<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04216407</url>
  </required_header>
  <id_info>
    <org_study_id>2019-01/02</org_study_id>
    <nct_id>NCT04216407</nct_id>
  </id_info>
  <brief_title>The Effects Of Remote Organ Ischemic Preconditioning On Systemic Inflammatory And Glycocalyx Integrity Parameters</brief_title>
  <official_title>The Effects Of Remote Organ Ischemic Preconditioning On Systemic Inflammatory And Glycocalyx Integrity Parameters In Living-Donor Liver Transplantation Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acibadem University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acibadem University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ischemia-reperfusion (IR) injury during liver transplantation is one of the major causes of
      mortality and morbidity associated with transplantation. Remote organ ischemic
      preconditioning (RIPC) is one of the most investigated practices to reduce IR injury. In this
      study, for the first time in the clinic, the effect of RIPC will be evaluated via both
      systemic inflammation parameters and also parameters showing glycocalyx integrity, on
      living-donor liver recipients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 5, 2019</start_date>
  <completion_date type="Actual">March 20, 2020</completion_date>
  <primary_completion_date type="Actual">January 17, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor necrosis factor-alpha (TNF-alpha)</measure>
    <time_frame>Postoperative early period (6 hours after intensive care unite admission)</time_frame>
    <description>Evaluation of TNF-alpha level difference between groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intercellular adhesion molecule-1 (ICAM-1)</measure>
    <time_frame>Postoperative early period (6 hours after intensive care unite admission)</time_frame>
    <description>Evaluation of (ICAM-1) level difference between group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypoxia-induced factor-1 (HIF-1)</measure>
    <time_frame>Postoperative early period (6 hours after intensive care unite admission)</time_frame>
    <description>Evaluation of HIF-1 level difference between groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin-8 (IL-8)</measure>
    <time_frame>Postoperative early period (6 hours after intensive care unite admission)</time_frame>
    <description>Evaluation of IL-8 level difference between groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Syndecan-1 (SDC-1)</measure>
    <time_frame>Postoperative early period (6 hours after intensive care unite admission)</time_frame>
    <description>Evaluation of SDC-1 level difference between groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>soluble Vascular cell adhesion molecule-1 (sVCAM-1).</measure>
    <time_frame>Postoperative early period (6 hours after intensive care unite admission)</time_frame>
    <description>Evaluation of sVCAM-1 level difference between groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>7 days after surgery</time_frame>
    <description>Early postoperative mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function tests</measure>
    <time_frame>7 days after surgery</time_frame>
    <description>Evaluation of early postoperative liver function tests; AST and ALT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in hospital and intensive care unit</measure>
    <time_frame>7 days after surgery</time_frame>
    <description>Evaluation of the length of stay in hospital and intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>7 days after surgery</time_frame>
    <description>Early postoperative complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Remote Organ Ischemic Preconditioning</condition>
  <arm_group>
    <arm_group_label>Remote Ischemic Preconditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Short-term tourniquet on to the lower extremity before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Remote ischemic preconditioning</intervention_name>
    <description>An orthopedic tourniquet was tied to the right lower extremities of the patients in RIPC arm, and tourniquet application was performed before the anhepatic phase in 3 periods of 3 minutes with an interval of 3 minutes.</description>
    <arm_group_label>Remote Ischemic Preconditioning</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients followed up by Acıbadem Hospital Organ Transplantation Center

          -  Patients accepted to participate in the study

          -  Older than 18 years of age

          -  ASA class III

          -  MELD score &gt;12

          -  Scheduled for elective liver transplantation surgery from a living donor

        Exclusion Criteria:

          -  Patients undergoing re-transplantation

          -  Under the age of 18 years

          -  Patients undergoing emergency surgery

          -  Patients with hepatorenal or hepatopulmonary syndrome

          -  Patients receiving mechanical ventilation support in the ICU

          -  Patients refusing to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Acıbadem Mehmet Ali Aydinlar University Atakent Hospital</name>
      <address>
        <city>Istanbul</city>
        <state>Atakent</state>
        <zip>34303</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 25, 2019</study_first_submitted>
  <study_first_submitted_qc>December 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Remote organ ischemic preconditioning</keyword>
  <keyword>Ischemia reperfusion injury</keyword>
  <keyword>Glycocalyx integrity parameters</keyword>
  <keyword>Systemic inflammation parameters</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

